Evidence map›Paper›PMID 42393724›Full record

ArticleJournal of hematology & oncology2026

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

Saikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, Abdelrahman M G Yousef, Mahmoud M G Yousef, Sacha El Khoury, Nicholas Hornstein, Ashlee Nichole Seldomridge, David Hong, Micheal J Overman and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Saikat Chowdhury *Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Ichiaki Ito *Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Vinay K PattalachintiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Abdelrahman M G YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Mahmoud M G YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Sacha El KhouryDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Nicholas HornsteinNorthwell Cancer Institute, New York, NY, USA.
Ashlee Nichole SeldomridgeDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David HongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Micheal J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA.
Melissa W TaggartDepartment of Pathology, Division of Pathology-Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wai Chin FooDepartment of Pathology, Division of Pathology-Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beth HelminkDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keith F FournierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe BLVD, Houston, TX, 77030, USA. JShen8@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Cancer Prevention and Research Institute of Texas RR180035Conquer Cancer Career Development Award 2022CDA-7604125121National Cancer Institute Cancer Center Support Grant P30 CA016672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundAppendiceal adenocarcinoma (AA) is a rare cancer with limited treatment options. KRAS is the most commonly mutated gene in AA and a promising therapeutic target, but its preclinical and translational relevance in AA remains unclear.

methodsWe evaluated KRAS

resultsMRTX1133 was highly effective for KRAS

conclusionsWhile effective suppression of RAS/ERK signaling by KRAS inhibitors reduces tumor growth, adaptive activation of EMT pathway may mediate resistance in KRAS

Indexed as

AdenocarcinomaAntineoplastic AgentsAppendiceal NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsFemaleHumansMaleMiceMutationTumor MicroenvironmentXenograft Model Antitumor AssaysAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)Appendix cancerKRASKRAS inhibitionPre-clincal modeling of cancerTargeted therapyTumor Microenvironment

Identifiers

PMID42393724
PMCPMC13536544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.